It is controversial whether acute myeloid leukemia (AML) patients with 20-29% bone marrow (BM) blasts should be considered AML or myelodysplastic syndromes (MDS). We retrospectively studied 382 patients, including 108 AML with 20-29% BM blasts (AML20-29), 210 AML with ≥30% BM blasts (AML ≥ 30), and 64 MDS with 10-19% BM blasts (MDS-EB2). We found that AML20-29 were more similar to MDS-EB2 in terms of advanced age, less blood count, the increased presence of poor-risk cytogenetics. The frequency of mutated genes in AML20-29 had both the characters of AML and MDS. Median overall survival of AML20-29 and MDS-EB2 were similar and shorter than those of AML ≥ 30 (p = .045). Multivariate analysis showed inferior survival with increased age, low platelet count and FLT3 mutations. Our findings suggest that AML20-29 have clinical features more similar to MDS than AML.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/10428194.2018.1515938 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Transition to Survivorship Care for Adolescents and Young Adults (AYAs) with Acute Leukemia: Provider Perspectives.
J Adolesc Young Adult Oncol
January 2025
Rutgers Cancer Institute, New Brunswick, New Jersey, USA.
Adolescent and young adult (AYA) survivors of acute lymphoblastic or myeloid leukemia diagnosed between the ages of 15 and 39 years are at risk for adverse late health effects following cancer treatment and require ongoing survivorship care. This study aims to understand the landscape of transitioning AYAs with leukemia from active treatment to survivorship care. A cross-sectional, anonymous online survey was sent out via listserv/email.
View Article and Find Full Text PDFBronchoscopic examination of an invasive aspergillosis in acute myeloid leukemia.
Intensive Care Med
January 2025
Department of Intensive Care, Hopital Universitaire de Bruxelles (HUB), Brussels, Belgium.
Acute leukemia in children: evaluating the necessity of routine biochemical analysis of cerebrospinal fluid.
Eur J Pediatr
January 2025
Pediatric Oncology and Hematology, Caen University Hospital, Avenue de La Côte de Nacre, 14000, Caen, France.
Unlabelled: Biochemical analyses of cerebrospinal fluid (CSF) are routinely performed at diagnosis in many pediatric oncology and hematology centers when acute leukemia is diagnosed. However, the clinical relevance of these analyses remains unclear. We conducted a retrospective analysis of biochemical CSF data from children diagnosed with acute leukemia at two French hospitals between 2016 and 2023 assessing the results in relation to the presence or absence of leukemic neuromeningeal involvement and the correlation between cytological and biochemical analyses.
View Article and Find Full Text PDFImpact of Pre-Treatment Comorbidity Burden on Survival in Patients Receiving Venetoclax Plus Hypomethylating Agents.
Am J Hematol
January 2025
IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy.
Expectation of survival of patients receiving HMA + VEN is influenced by pre-treatment comorbidity burden.
View Article and Find Full Text PDFLncRNA HOXA10-AS as a novel biomarker and therapeutic target in human cancers.
Front Mol Biosci
January 2025
Department of Immunology, School of Clinical and Basic Medical Sciences, Shandong First Medical University, Jinan, Shandong, China.
Long non-coding RNAs (lncRNAs) are crucial regulatory molecules that participate in numerous cellular development processes, and they have gathered much interest recently. HOXA10 antisense RNA (HOXA10-AS, also known as HOXA-AS4) is a novel lncRNA that was identified to be dysregulated in some prevalent malignancies. In this review, the clinical significance of HOXA10-AS for the prognosis of various cancers is analyzed.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!